Heron Therapeutics
(HRTX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2009 | 03-2009 | 12-2008 | 09-2008 | 06-2008 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 3,610 | 7,110 | 9,967 | 15,680 | 20,356 |
| Marketable Securities | 194 | 374 | 571 | 859 | 1,164 |
| Receivables | 11 | 8 | 32 | 32 | 152 |
| TOTAL | $3,980 | $7,746 | $10,816 | $16,894 | $22,161 |
| Non-Current Assets | |||||
| PPE Net | 684 | 788 | 881 | 1,060 | 1,163 |
| Other Non-Current Assets | 128 | 103 | 103 | 103 | 103 |
| TOTAL | $812 | $891 | $984 | $1,163 | $1,266 |
| Total Assets | $4,792 | $8,637 | $11,800 | $18,057 | $23,427 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 554 | 689 | 344 | 715 | 1,285 |
| Accrued Expenses | 1,860 | 2,075 | 2,843 | 4,976 | 3,830 |
| TOTAL | $2,414 | $2,764 | $3,187 | $5,691 | $5,115 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 0 | 0 | 15 | 72 | 131 |
| TOTAL | $1,000 | $1,000 | $1,015 | $1,072 | $1,131 |
| Total Liabilities | $3,414 | $3,764 | $4,202 | $6,763 | $6,246 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 1,569 | 1,550 | 1,547 | 1,547 | 1,545 |
| Common Shares | 139,337 | 138,906 | 309 | 138,463 | 138,135 |
| Retained earnings | -137,953 | -134,012 | -131,051 | -127,106 | -120,900 |
| Other shareholders' equity | -6 | -21 | -43 | -63 | -54 |
| TOTAL | $1,378 | $4,873 | $7,598 | $11,294 | $17,181 |
| Total Liabilities And Equity | $4,792 | $8,637 | $11,800 | $18,057 | $23,427 |